ImmunityBio (IBRX) Change in Accured Expenses (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Change in Accured Expenses data on file, last reported at $3.1 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 124.26% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $19.3 million, a 448.55% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, up 311.14% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $3.1 million, up from $1.9 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for IBRX reached as high as $18.6 million in Q1 2023 and fell as low as -$19.5 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged $917882.4 across 5 years, with a median of $3.1 million in 2026.
• Across the five-year window, Change in Accured Expenses surged 675.33% in 2022 and slumped 519.36% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at -$3.2 million in 2022, then slumped by 519.36% to -$19.5 million in 2023, then jumped by 89.17% to -$2.1 million in 2024, then soared by 191.06% to $1.9 million in 2025, then soared by 62.96% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $3.1 million in Q1 2026, $1.9 million in Q4 2025, and $5.5 million in Q3 2025.